San Diego-based Tandem Diabetes Care, Inc. designs, develops and markets products for people with insulin-dependent diabetes. Its flagship product, the t:slim X2 Insulin Delivery System, or t:slim X2, is based on the proprietary technology platform. Control-IQ technology, launched in January 2020, is an advanced hybrid-closed loop feature, designed to help increase a user’s time in targeted glycemic range. It is the first and only system cleared to deliver automatic correction boluses in addition to adjusting insulin to help prevent fluctuations in blood sugar levels.

Per the company, t:slim X2 is the smallest durable insulin pump available and is also the only available pump capable of remote feature updates. Notably, in 2018 Tandem Diabetes launched the t:slim X2 Insulin Pump in select geographies.

As part of the AID (automated insulin delivery) systems, the company offers pump integration with multiple CGM sensors, which helps provide customizable solutions for people living with diabetes. In December 2023, the company began offering the t:slim X2 pump integrated with the Dexcom G7 sensor, which is the fourth generation of Dexcom’s CGM that the company has integrated with its pump technology since 2015.The company also provides Tandem Device Updater to help customers update their pump’s software and is compatible with PC and Mac.

Tandem Diabetes’ portfolio also comprises a web-based data management platform, Tandem Source, which provides the users, their caregivers and their healthcare providers with a fast, easy and visual way to display therapy management data from the pump and supported blood glucose meters. The company also has a popular mobile app, Sugarmate, which allows users to log glucose data and health and nutrition information and can provide notifications and alerts to users, their family and their caregivers. In 2023,the company reported a revenue decline of 11% from 2022.

In addition, Tandem Diabetes considers opportunities to expand its business through acquisitions of products or technologies, or investments in other businesses. In July 2022, the company acquired an infusion set developer, Capillary Biomedical, Inc. (Capillary Biomedical).  In January 2023, it completed the acquisition of AMF Medical SA, which complements its family of insulin delivery offerings and also expands addressable market opportunities.